NYSE:NVS - Novartis Stock Price, Price Target & More

$79.00 -2.70 (-3.30 %)
(As of 04/20/2018 08:31 AM ET)
Previous Close$81.70
Today's Range$78.81 - $79.82
52-Week Range$73.31 - $94.19
Volume5.93 million shs
Average Volume1.75 million shs
Market Capitalization$189.34 billion
P/E Ratio16.42
Dividend Yield3.64%
Beta0.74

About Novartis (NYSE:NVS)

Novartis logoNovartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.31%
Current Ratio1.21%
Quick Ratio0.91%

Price-To-Earnings

Trailing P/E Ratio16.42
Forward P/E Ratio14.91
P/E Growth1.84

Sales & Book Value

Annual Sales$49.11 billion
Price / Sales3.73
Cash Flow$7.3970 per share
Price / Cash10.68
Book Value$32.03 per share
Price / Book2.47

Profitability

EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins15.69%
Return on Equity16.03%
Return on Assets8.53%

Miscellaneous

Employees121,597
Outstanding Shares2,317,460,000

How to Become a New Pot Stock Millionaire

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis declared that its Board of Directors has initiated a share repurchase plan on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.9% of its shares through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

How were Novartis' earnings last quarter?

Novartis (NYSE:NVS) announced its quarterly earnings results on Thursday, April, 19th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.25 by $0.03. The firm earned $12.69 billion during the quarter, compared to the consensus estimate of $12.45 billion. Novartis had a net margin of 15.69% and a return on equity of 16.03%. The company's revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.13 EPS. View Novartis' Earnings History.

What price target have analysts set for NVS?

10 analysts have issued 12 month price objectives for Novartis' stock. Their forecasts range from $82.25 to $91.00. On average, they anticipate Novartis' stock price to reach $87.75 in the next twelve months. View Analyst Ratings for Novartis.

Are investors shorting Novartis?

Novartis saw a decrease in short interest in March. As of March 15th, there was short interest totalling 1,430,834 shares, a decrease of 34.1% from the February 28th total of 2,172,080 shares. Based on an average trading volume of 1,766,483 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the shares of the company are sold short.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 53)
  • Mr. André Wyss, Pres of Operations & Country Pres of Switzerland (Age 51)
  • Dr. Felix R. Ehrat Ph.D., Group Gen. Counsel (Age 61)
  • Mr. Steven Baert, Head of HR (Age 44)

Has Novartis been receiving favorable news coverage?

News stories about NVS stock have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a news impact score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $79.00.

How big of a company is Novartis?

Novartis has a market capitalization of $189.34 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  694
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (NYSE:NVS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Novartis in the last 12 months. Their average twelve-month price target is $87.75, suggesting that the stock has a possible upside of 11.08%. The high price target for NVS is $91.00 and the low price target for NVS is $82.25. There are currently 3 sell ratings, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.801.802.002.14
Ratings Breakdown: 3 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.75$87.75$84.4050$82.9240
Price Target Upside: 11.08% upside1.00% upside2.85% downside2.96% downside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Deutsche BankReiterated RatingNeutralLowView Rating Details
4/9/2018JPMorgan ChaseReiterated RatingNeutralLowView Rating Details
1/15/2018UBSReiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralMediumView Rating Details
12/6/2017Bank of AmericaDowngradeNeutral -> UnderperformLowView Rating Details
10/25/2017BarclaysDowngradeEqual Weight -> UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 -> $91.00N/AView Rating Details
8/9/2017CowenSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight -> OverweightLowView Rating Details
7/5/2017Credit Suisse GroupDowngradeNeutral -> Underperform$82.25MediumView Rating Details
3/22/2017Goldman SachsReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold -> Buy$73.82 -> $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral -> UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold -> BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy -> HoldN/AView Rating Details
10/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 -> $92.00N/AView Rating Details
5/24/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Earnings Estimates

2018 EPS Consensus Estimate: $5.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.24$1.31$1.28
Q2 20181$1.34$1.34$1.34
Q3 20181$1.35$1.35$1.35
Q4 20181$1.50$1.50$1.50

Novartis (NYSE NVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/19/2018Q1$1.25$1.28$12.4515 billion$12.6940 billionViewN/AView Earnings Details
1/24/2018n/a$1.16$1.20$12.6464 billion$12.9150 billionViewListenView Earnings Details
10/24/20179/30/2017$1.25$1.29$12.2102 billion$12.4130 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.2043 billion$12.2420 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.5933 billion$11.5390 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.4407 billion$12.3220 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.1260 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.9350 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3 2014$1.29$1.28$14.1420 billion$14.7040 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.8283 billion$14.6370 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.2526 billion$14.0220 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.0780 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.0160 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
10/21/2010Q3 2010$1.20$1.36ViewN/AView Earnings Details
7/15/2010Q2 2010$1.13$1.20ViewN/AView Earnings Details
1/26/2010Q4 2009$1.16$1.01ViewN/AView Earnings Details
10/22/2009Q3 2009$0.95$0.92ViewN/AView Earnings Details
4/23/2009Q1 2009$0.87$0.87ViewN/AView Earnings Details
1/28/2009Q4 2008$0.79$0.66ViewN/AView Earnings Details
10/20/2008Q3 2008$0.99$0.92ViewN/AView Earnings Details
7/17/2008Q2 2008$0.93$0.99ViewN/AView Earnings Details
1/23/2008Q4 2007$0.67$0.41ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novartis (NYSE:NVS) Dividend Information

Novartis pays an annual dividend of $2.98 per share, with a dividend yield of 3.77%. NVS's most recent annual dividend payment was Friday, March 3. Novartis pays out 61.95% of its earnings out as a dividend.
Most Recent Dividend:3/3/2017
Annual Dividend:$2.98
Dividend Yield:3.77%
Dividend Growth:-0.50% (3 Year Average)
Payout Ratio:61.95% (Trailing 12 Months of Earnings)
56.23% (Based on This Year's Estimates)
53.21% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.32703/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.71863.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.76%
Insider Trading History for Novartis (NYSE:NVS)
Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
BRIEF-Novartis says EXPAND study shows siponimods (Baf312) efficacyBRIEF-Novartis says EXPAND study shows siponimod's (Baf312) efficacy
www.reuters.com - April 20 at 8:09 AM
New Novartis analyses at AAN show siponimods efficacy on disability and cognition in secondary progressive MS ...New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS ...
globenewswire.com - April 20 at 8:09 AM
Novartis (NVS) Earns Neutral Rating from Deutsche BankNovartis (NVS) Earns Neutral Rating from Deutsche Bank
www.americanbankingnews.com - April 20 at 6:38 AM
Novartis (NVS) Misses Q1 EPS by 1c, Revenue BeatsNovartis (NVS) Misses Q1 EPS by 1c, Revenue Beats
www.streetinsider.com - April 19 at 5:52 PM
Novartis CEO feels heat on US generics, Cosentyx dropNovartis CEO feels heat on US generics, Cosentyx drop
www.reuters.com - April 19 at 5:52 PM
Novartis Stock Dips After Cosentyx Sales, Sandoz Generics DisappointNovartis Stock Dips After Cosentyx Sales, Sandoz Generics Disappoint
finance.yahoo.com - April 19 at 5:52 PM
Novartis (NVS) Given a $77.00 Price Target at CowenNovartis (NVS) Given a $77.00 Price Target at Cowen
www.americanbankingnews.com - April 19 at 5:50 PM
Novartis AG (ADR) Stock Drops on Q1 Earnings MissNovartis AG (ADR) Stock Drops on Q1 Earnings Miss
investorplace.com - April 19 at 2:21 PM
Novartis (NVS) Announces  Earnings ResultsNovartis (NVS) Announces Earnings Results
www.americanbankingnews.com - April 19 at 9:27 AM
BRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targetsBRIEF-Novartis expects cost cuts, rising Entresto, Cosentyx sales to help meet 2018 op. profit targets
www.reuters.com - April 19 at 8:04 AM
UPDATE 1-Novartis confirms 2018 targets as Alcon recovery gains steamUPDATE 1-Novartis confirms 2018 targets as Alcon recovery gains steam
www.reuters.com - April 19 at 8:04 AM
Novartis Q1 Profit Climbs, Misses Estimates; Backs FY18 View - Quick FactsNovartis Q1 Profit Climbs, Misses Estimates; Backs FY18 View - Quick Facts
www.nasdaq.com - April 19 at 8:04 AM
Novartis confirms 2018 targets as Alcon recovery gains steamNovartis confirms 2018 targets as Alcon recovery gains steam
www.reuters.com - April 19 at 8:04 AM
Novartis delivered a strong first quarter and acted to become a more focused medicines companyNovartis delivered a strong first quarter and acted to become a more focused medicines company
globenewswire.com - April 19 at 8:04 AM
[$$] Cancer and heart drugs boost Novartis sales [$$] Cancer and heart drugs boost Novartis sales 
finance.yahoo.com - April 19 at 8:04 AM
New Novartis CEO feels heat on U.S. generics businessNew Novartis CEO feels heat on U.S. generics business
finance.yahoo.com - April 19 at 8:04 AM
Novartis: 1Q Earnings SnapshotNovartis: 1Q Earnings Snapshot
finance.yahoo.com - April 19 at 8:04 AM
Vyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth DriverVyxeos Could Be Jazz Pharmaceuticals’ Long-Term Growth Driver
finance.yahoo.com - April 19 at 8:04 AM
Novartis Earnings Top, But Key Drug, Generics Sales DisappointNovartis Earnings Top, But Key Drug, Generics Sales Disappoint
finance.yahoo.com - April 19 at 8:04 AM
Novartis to invest $100M to develop antimalarialsNovartis to invest $100M to develop antimalarials
www.marketwatch.com - April 18 at 8:05 AM
Glaxo, Novartis Join $4 Billion Gates-Led Push to Fight MalariaGlaxo, Novartis Join $4 Billion Gates-Led Push to Fight Malaria
www.bloomberg.com - April 18 at 8:05 AM
Form SC TO-T AveXis, Inc. Filed by: NOVARTIS AGForm SC TO-T AveXis, Inc. Filed by: NOVARTIS AG
www.streetinsider.com - April 17 at 6:08 PM
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab ...Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab ...
globenewswire.com - April 17 at 6:08 PM
BRIEF-Novartis to invest $100 Mln over 5 years in anti-malarial drugsBRIEF-Novartis to invest $100 Mln over 5 years in anti-malarial drugs
www.reuters.com - April 17 at 8:10 AM
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next ...Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next ...
globenewswire.com - April 17 at 8:10 AM
Novartis tender offer for AveXis commencesNovartis tender offer for AveXis commences
finance.yahoo.com - April 17 at 8:10 AM
What Novartis Bought in AveXisWhat Novartis Bought in AveXis
www.fool.com - April 16 at 5:38 PM
Did Novartis Overpay for AveXis?Did Novartis Overpay for AveXis?
finance.yahoo.com - April 16 at 5:38 PM
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic ...Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic ...
globenewswire.com - April 16 at 8:04 AM
Novartis to Post Q1 2018 Earnings of $1.24 Per Share, Jefferies Group Forecasts (NVS)Novartis to Post Q1 2018 Earnings of $1.24 Per Share, Jefferies Group Forecasts (NVS)
www.americanbankingnews.com - April 16 at 1:19 AM
Why GlaxoSmithKlines share price could be about to skyrocketWhy GlaxoSmithKline's share price could be about to skyrocket
www.fool.co.uk - April 15 at 8:53 AM
Glaxo to Sell Rare Disease Gene Therapies to Private BiotechGlaxo to Sell Rare Disease Gene Therapies to Private Biotech
finance.yahoo.com - April 13 at 8:05 AM
Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive DrugsNovartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs
www.forbes.com - April 12 at 5:54 PM
GlaxoSmithKline Buys Novartis’s Stake in Joint VentureGlaxoSmithKline Buys Novartis’s Stake in Joint Venture
finance.yahoo.com - April 12 at 5:54 PM
Zacks: Brokerages Expect Novartis (NVS) to Post $1.33 EPSZacks: Brokerages Expect Novartis (NVS) to Post $1.33 EPS
www.americanbankingnews.com - April 12 at 8:32 AM
Incyte Has Diversified Its Revenues across Multiple Product LinesIncyte Has Diversified Its Revenues across Multiple Product Lines
finance.yahoo.com - April 12 at 8:07 AM
A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock NeedsA Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs
investorplace.com - April 12 at 7:51 AM
Novartis (NVS) Set to Announce Earnings on ThursdayNovartis (NVS) Set to Announce Earnings on Thursday
www.americanbankingnews.com - April 12 at 1:25 AM
Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And MoreBiotech Stock Roundup: Spectrum Up, Incyte Down, AveXis To Merge With Novartis And More
feeds.benzinga.com - April 11 at 3:32 PM
Novartis (NVS) Given a $90.00 Price Target at CowenNovartis (NVS) Given a $90.00 Price Target at Cowen
www.americanbankingnews.com - April 11 at 1:21 PM
Biotech Analysis Central Pharma News: Novartiss Gene Therapy Catch, AstraZenecas NASH Move, Cloviss ...Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's ...
seekingalpha.com - April 11 at 8:10 AM
Tuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizuresTuberous Sclerosis Alliance salutes FDA approval of Afinitor® DISPERZ (everolimus) as the first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures
www.prnewswire.com - April 10 at 11:34 PM
Novartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizuresNovartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizures
www.prnewswire.com - April 10 at 9:31 PM
Novartis (NVS) Downgraded by BidaskClubNovartis (NVS) Downgraded by BidaskClub
www.americanbankingnews.com - April 10 at 7:17 PM
Rare Diseases Command Mega Prices With Novartis Wager on AveXisRare Diseases Command Mega Prices With Novartis Wager on AveXis
www.bloomberg.com - April 10 at 8:11 AM
Regenxbio Inc. (RGNX) PT Raised to $90 at Chardan Capital Markets on Novartis-AveXis; Could Also Become a TargetRegenxbio Inc. (RGNX) PT Raised to $90 at Chardan Capital Markets on Novartis-AveXis; Could Also Become a Target
www.streetinsider.com - April 10 at 8:11 AM
Why Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: A Journey To Focus On Data And DigitalWhy Did Novartis Spend $9 Billion On Gene Therapy? CEO Says: 'A Journey To Focus On Data And Digital'
www.forbes.com - April 10 at 8:11 AM
Novartis' Acquisition of Avexis: Bad News for Biogen?Novartis' Acquisition of Avexis: Bad News for Biogen?
finance.yahoo.com - April 10 at 8:11 AM
Novartis AG -- Moodys: $8.7 billion acquisition of AveXis strengthens Novartiss pipeline in gene therapy, but reduces financial flexibilityNovartis AG -- Moody's: $8.7 billion acquisition of AveXis strengthens Novartis's pipeline in gene therapy, but reduces financial flexibility
finance.yahoo.com - April 10 at 8:11 AM
Focus: Lonzas virus factory shows gene therapys Texas-sized promiseFocus: Lonza's virus factory shows gene therapy's Texas-sized promise
finance.yahoo.com - April 10 at 8:11 AM

SEC Filings

Novartis (NYSE:NVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novartis (NYSE NVS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.